Drug Therapy: Dopamine Agonists

Poewe, Werner

doi:10.1016/b978-0-7506-5428-9.50006-8

Cited by 5 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The regulatory and optimal dose of cabergoline in Japan is similar to that of western countries, but the optimal dose of pergolide in Japan and Korea is low compared with that of western countries (Table 1). This may suggest that the EU data [20] frequency of valvular regurgitation may be associated with the dose of pergolide and cabergoline. The results of these reports suggest that overt clinical heart disease seems to be much rarer than echocardiographical abnormalities with regurgitation from several case-control studies [10,17,18,34] after Van Camp et al [31].…”

Section: ■ Cohort Studymentioning

confidence: 88%

“…However, the regulatory daily dose of pergolide in Japan (0.75-1.25 mg/day) is lower than that in EU countries (0.75-5 mg/day), and this may explain the discrepancy of observed frequency of valvular regurgitation in patients taking pergolide in the two regions. A relatively high dose of pergolide (2.25 mg/day) induced VHD with surgery for valve replacement [20]. The affinity towards 5HT 2B receptors of lisuride, dopamine agonist, is very low and that of bromocriptine fairly low (Fig.…”

Section: ■ Reversibilitymentioning

confidence: 98%

See 1 more Smart Citation

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery

Yamamoto

Uesugi

2007

J Neurol

View full text Add to dashboard Cite

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mysterySince the first case report [28], further case reports [4,7,8,19,21,27,30], one observational report [2], case-control studies [12,17,18,[31][32][33][34], and one cohort study [26] conducted in PD patients have demonstrated similar findings of fibrotic VHD caused by ergot dopamine ag-JON 5012 ■ Abstract High doses of the ergot dopamine agonists, pergolide and cabergoline, frequently cause valvular regurgitation and, somewhat less frequently, valvular heart disease (VHD) in Parkinson's disease. Most patients with valvular regurgitation have no cardiac signs

show abstract

Section: ■ Cohort Studymentioning

confidence: 88%

Section: ■ Reversibilitymentioning

confidence: 98%

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery

Yamamoto

Uesugi

2007

J Neurol

View full text Add to dashboard Cite

show abstract

“…This receptors are defined by capacity to stimulate (type D1) or to inhibit (type D2) the adenylciclase. This capacity reflects its different interactions with the G-protein, wich can to possess the sequences of different amino acids, tha justifies the specificity of each receptor 11 . A nigral axon can to influence both types of receptors in the group of striatal neurons responsible for muscular contraction agonistantagonist, proportionating the dopaminergic effect on the agonist (acceleration of the contraction) and antagonist (reduction of the tonus) skeletal muscle during the moviment 12 …”

Section: Review Of Literaturementioning

confidence: 99%

Interferência do tratamento medicamentoso imediato e tardio na doença de Parkinson no gerenciamento da disfagia

et al. 2014

View full text Add to dashboard Cite

A Doença de Parkinson apresenta grande incidência na população idosa, gerando comprometimento motor progressivo, que afeta várias funções, dentre as quais se destaca a deglutição. Esse trabalho teve como objetivo relacionar a disfagia na Doença de Parkinson aos efeitos imediatos e/ou tardios do tratamento medicamentoso, que de forma direta ou indireta interferirá no gerenciamento fonoaudiológico. Fizemos uma revisão de literatura nas bases de dados eletrônicas Lilacs, Scielo, Medline e Pubmed no período de 2001 a 2011, utilizando os termos livres “Doença de Parkinson”; (Parkinson Disease), “deglutição”; (deglutition), “disfagia”; (dysphagia), “preparações farmacêuticas”; (pharmaceutical preparations), “levodopa”;, “videofluoroscopia”; (videofluoroscopy), além de um documento governamental (OPAS, 2002), artigos relevantes e exemplares da literatura americana e brasileira sobre o tema. A literatura aponta a Levodopa como o principal tratamento farmacológico da doença de Parkinson. Contudo, a melhora dos sintomas motores deve ser ponderada em função da ocorrência de efeitos colaterais importantes, sejam imediatos ou tardios. Até o momento não há respostas consistentes a favor da melhora da disfagia como resultado do tratamento farmacológico, cujos efeitos podem interferir direta ou indiretamente sobre as manifestações disfágicas e de várias formas. Assim, torna-se fundamental o registro das medicações como parte da anamnese, considerando que tais dados possam auxiliar na orientação/reorientação da conduta fonoaudiológica, especialmente em contexto interdisciplinar. A despeito da possibilidade do doente de Parkinson responder de forma inconsistente à terapia farmacológica, vale ressaltar que o profissional deve estar atento à presença de efeitos colaterais como fatores modificadores do quadro de disfagia orofaríngea na Doença de Parkinson idiopática.

show abstract

“…Существуют некоторые отличия между современными АДР в их рецепторном профиле [9]. Но противопаркинсо-нический эффект связан со стимуляцией D2-рецепторов [6,10].…”

unclassified

“…Во-первых, это их прямое действие на постсинаптические рецепторы в обход дегенерирующих нейронов черной субстанции, не связанное с образовани-ем ДА и активностью каких-либо ферментов, например катехол-О-метилтрансферазы (КОМТ) или моноаминок-сидазы (МАО) [10].…”

unclassified

A current view on dopamine receptor agonists in the treatment of Parkinson’s disease

2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Drug Therapy: Dopamine Agonists

Cited by 5 publications

References 4 publications

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery

Interferência do tratamento medicamentoso imediato e tardio na doença de Parkinson no gerenciamento da disfagia

A current view on dopamine receptor agonists in the treatment of Parkinson’s disease

Contact Info

Product

Resources

About